Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Bortezomib, Dexamethasone, and Metronomic Cyclophosphamide in Elderly Myeloma
NCT02082405Phase 2Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Apr 2015
- Primary completion
- Aug 2016
- Modality
- Modified Peptides, Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, cyclophosphamide and dexamethasone in multiple myeloma (MM), sponsored by Case Comprehensive Cancer Center. Primary endpoints: Overall Response Rate up to 7 months and Incidence of Toxicities up to 7 months. Planned start Apr 2015; status: withdrawn.
02
Drugs
bortezomibcyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02082405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082405.